Jax DiEugenio

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.

177Lu-PNT2002 improved radiographic progression-free survival in PSMA-positive mCRPC after progression on an ARPI.

Binod Dhakal, MD, MS, discusses updated survival data from the CARTITUDE-4 trial of cilta-cel in pretreated, lenalidomide-refractory multiple myeloma.

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.